Kyushu University · Medicine
Professor Tomoyoshi Takenaka's research lab focuses on translational oncology in non-small cell lung cancer (NSCLC), with a strong emphasis on biomarkers for treatment response and prognosis. The lab investigates DNA repair enzyme expression, EGFR mutation status, and metabolic activity (e.g., FDG-PET SUVmax) to predict chemosensitivity and therapeutic outcomes. Key research directions include identifying biological predictors of response to targeted therapies and chemotherapy, as well as exploring the role of tumor microenvironment markers such as Ki-67 and VEGF. The lab also examines clinical factors influencing recurrence and postoperative complications, particularly in relation to smoking history and treatment strategies.
Figures are computed from collected data and may differ slightly.
DNA repair enzyme expression in tumor cells possibly affects sensitivity to anti-cancer agents. The aim of this study was to determine the relationship between expression status of DNA repair enzymes and chemosensitivity in patients with non-small cell lung cancer (NSCLC). NSCLC tissues prepared from the surgical specimens of 41 patients were subjected to immunohistochemical analysis for Rad51 and ERCC1 proteins and to a chemosensitivity test using the MTT assay. The relationships between the ex
It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.
The PRS of patients with recurrent NSCLC was different depending on the patient's background characteristics and initial treatment for recurrence.
The SUV(max) was associated with the expression of Ki-67 and VEGF in NSCLC. These findings indicated that the SUV(max) of primary tumors might therefore reflect the biological malignant potential in NSCLC.
Short-term smoking cessation intervention did not enough reduce the PPCs as much as in former or never smokers.
Thymoma is an epithelial neoplasm of the thymus, which commonly lies in the anterior mediastinum and, therefore, an intrathoracic origin is considered to be rare. This report presents a case of giant thymoma arising in the thoracic cavity. A 61-year-old male presented with a chronic cough and breathlessness. Chest CT revealed a well enhanced giant mass approximately 18 cm in diameter in the right thoracic cavity. FDG-PET showed that the SUVmax of the tumor was 5.0 in the center and almost 2.5 in
The PNI might help clinicians appropriately identifying patients with better treatment outcomes when receiving first-line ICI therapy.
The distance between home and the hospital was not found to influence the long-term outcomes of the patients with surgically resected NSCLC. Therefore, the travel distance should not represent a contraindication to surgical resection and postoperative therapy for NSCLC.
Open papers in the app to read, cite, and organize with AI.
